Health Advances has been successfully advising companies on how best to commercialize diagnostics for the past two decades. Our experienced multi-disciplinary team includes PhD researchers, clinical pathologists, and diagnostics industry leaders working to provide therapeutics, diagnostics, and life science companies with innovative strategies.
Deep understanding of stakeholder perspectives to create a successful commercialization strategy.
Developed a comprehensive strategy for the worldwide commercialization of an oncology companion diagnostic
Created a manual to educate country managers within a pharma company on companion diagnostic launch strategy and tactics
Evaluated the expected impact of different companions on worldwide oncology drug revenues and aided in the selection of companion diagnostic developers
Identified anticipated pain points associated with a immuno-oncology CDx to help a pharma company refine its testing strategy
Navigated a complex technology selection process for a companion, resulting in recommendations for near- and long-term technology choices
Identified and prioritized potential partners for commercialization of a novel oncology diagnostic
Recommended tactics to address major barriers to companion diagnostic access and encourage widespread testing prior to novel drug launch
Developed tactics to address hurdles in adoption of liquid biopsy for resistance mutation testing in NSCLC